Catheter ablation of atrial fibrillation
Authors:
R. Lábrová; J. Špinar
Authors place of work:
Interní kardiologická klinika LF MU a FN Brno
Published in the journal:
Kardiol Rev Int Med 2008, 10(3): 103-110
Summary
Atrial fibrillation is the most frequent disorder of heart rhythm with constantly increasing incidence and prevalence. Although pharmacotherapy remains the primary method of choice to treat the fibrillation it slowly becomes ineffective and may produce side effects and adverse events. The selective catheter ablation interferes with the pathophysiological mechanism of onset and preservation of atrial fibrillation and as a result it restitutes sinus rhythm. In paroxysmal atrial fibrillation we usually electrically isolate active ectopic foci in pulmonary veins antrums. In persistent or permanent form of atrial fibrillation we perform a more complex ablation because in these cases electrical and functional atrial remodelation has already developed. Besides performing wider circle leasions around the pulmonary veins antrums we proceed with another linear leasions in the left atrium, sometimes in the right atrium and coronary sinus, respectively. Such leasions affect reentry circles in atrial wall that help the fibrillation preserve. The catheter ablation of paroxysmal atrial fibrillation has become a routine treatment modality in symptomatic patients resistent to antiarrhytmic drugs. Also increasing amount of patients with an organic heart disease with or without heart failure are being indicated to the catheter ablation. The restitution of sinus rhythm may improve or fully normalize the systolic function of the left ventricle. To make catheter ablations less time-consuming and less technically difficult new sophisticated techniques are being explored.
Key words:
atrial fibrillation – paroxysmal – persistent – permanent – radiofrequency catheter ablation – electrical isolation of pulmonary veins – combination techniques
Zdroje
1. Lévy S, Breithardt G, Campbell RWF et al. Atrial fibrillation: Current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998; 19: 1294-1320.
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
3. Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93–100.
4. Israel CW, Grönefeld G, Ehrlich JR et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43: 47–52.
5. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006; 27: 1979-2030.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–988.
7. Madrid AH, Escobar C, Rebollo JM et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev 2003; 7: 243–246.
8. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342: 913-920.
9. Hohnloser SH. Indications and limitations of class II and III antiarrhytmic drugs in atrial fibrillation. Pacing Clin Electrophysiol 1994; 17: 1019-1025.
10. Torp-Pedersen C, Møller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-865.
11. Wazni OM, Marrouche NF, Martin DO et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634-2640.
12. Pappone C, Rosanio S, Augello G et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for antrial fibrillation. J Am Coll Cariol 2003; 42: 185-197.
13. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, patophysiology, and rationale for therapy. Am J Cardiol 2003; 90: D2-D8.
14. Priori SG, Aliot E, Blomstrom-Lundquist C et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001; 22: 1374-1450.
15. Oral H, Pappone C, Chung A et al. Circumferantial pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354: 934-941.
16. Mestroni L. Genomic medicine in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2193-2196.
17. McGovern PG, Jacobs DR Jr, Shahar E et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota Heart Survey. Circulation 2001; 104: 19-24.
18. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol 2003; 42: 1206-1207.
19. Falk RH. Atrial fibrillation. N Engl J Med 2001; 344: 1067-1078.
20. Cherf D. Studies on auricular tachycardia caused by aconitine administration. Proc Soc Exp Biol Med 1947; 64: 233-239.
21. Allessie M, Lammers WJEP, Bonke FIM et al. Experimental evaluation of Moe´s multiple wavelet hypothesis of atrial fibrillation. In: Zipes DP, Jalife J (eds). Cardiac Electrophysiology and Arrhytmias. New York. Grune and Stratton 1985: 265-275.
22. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J 1964; 67: 200-220.
23. Cox JL, Schuessler RB, Boineau JP. The development of the Maze procedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg 2000; 12: 2-14.
24. Sueda T, Nagata H, Shikata H et al. Simple left atrial procedure for chronic atrial fibrillation associated with mitral valve disease. Ann Thorac Surg 1996; 62: 1796-1800.
25. Haïssaguerre M, Jaïs P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
26. Nademanee K, Schwab MC, Kosar E et al. A new approach for catheter ablation of atrial fibrillation mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43: 2044-2053.
27. Špinar J, Vítovec J. Losartan – víc než pokles krevního tlaku. Kardiol Rev 2006; 8: 115-120.
28. Haïssaguerre M, Jaïs P, Shah DC et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132–1144.
29. Haïssaguerre M, Gencel L, Fischer B et al. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994; 5: 1045-1052.
30. Haïssaguerre M, Shah DC, Jais P et al. Electrophysiological break-throughs from the left atrium to the pulmonary veins. Circulation 2000; 101: 1409-1417.
31. Marrouche NF, Dresing T, Cole C et al. Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation. J Am Coll Cardiol 2002; 40: 464–474.
32. Oral H, Chugh A, Good E et al. A tailored approach to catheter ablation of paroxysmal atrial fibrillation. Circulation 2006; 113: 1824-1831.
33. Fiala M, Chovančík J, Heinz P et al. Léčba symptomatické intermitentní fibrilace síní katetrovou ablací v levé srdeční síni: bezprostřední a dlouhodobé výsledky u 150 pacientů. Vnitr Lek 2005; 51: 971-983.
34. Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93–100.
35. Pappone C, Oreto G, Rosanio S et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation. Efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001; 104: 2539-2544.
36. Ouyang F, Bänsch D, Ernst S et al. Complete isolation of the left atrium surrounding the pulmonarz veins: new insights form the double-lasso technique in paroxysmal atrial fibrillation. Circulation 2004; 110: 2090-2096.
37. Pappone C, Santinelli V, Manguso F et al. Pulmonary vein denervation enhances long.term benebit after circumferential ablation for paroxysmal aatrial fibrillation. Circulation 2004; 109: 327-334.
38. Nademanee K, Schwab MC, Kosar E et al. A new approach for catheter ablation of atrial fibrillation mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43: 2044-2053.
39. Lévy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA Study. The College of French Cardiologists. Circulation 1999; 99: 3028-3035.
40. Hsu LF, Jaïs P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004; 351: 2373-2383.
41. Oral H, Pappone C, Chung A et al. Circumferantial pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354: 934-941.
42. Haïssaguerre M, Sanders P, Hocini M et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termintion. J Cardiovasc Electrophysiol 2005; 16: 1125-1137.
43. Cappato R, Calkins H, Chen SA et al. Worldwide survey on the methods, efficacy and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-1105.
44. Malchano ZJ, Neuzil P, Cury RC et al. Integration of cardiac CT/MR imaging with three-dimensional electroanatomical mapping to guide catheter manipulation in the left atrium: implications for catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2006; 17: 1221-1229.
45. Marrouche N, Martin DO, Wazni O et al. Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outcome and complications. Circulation 2003; 107: 2710-2716.
46. Pappone C, Vecedomini G, Manguso F et al. Robotic magnetic navigation for atrial fibrillation ablation. J Am Coll Cardiol 2006; 47: 1390-1400.
47. Reddy VY, Houghtaling C, Fallon J et al. Use of a diode laser ballon ablation catheter to generate circumferential pulmonary venous lesions in an open-thoracotomy caprine model. Pacing Clin Electrophysiol 2004; 27: 52-57.
48. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcome after ablation and pacing therapy for atrial fibrillation: a meta analysis. Circulation 2000; 101: 1138-1144.
49. Gasparini M, Aurichio A, Metra M et al. Long term survival in patients undergoing cardiac resynchronisation therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrail fibrillation. Eur Heart J 2008; 29: 1644-52
50. Leciercq C, Mabo P. Cardiac resynchronisation therapy and atrial fibrillation. Do we have final answer? Eur Heart J 2008; 29: 1597-1599.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2008 Číslo 3
Najčítanejšie v tomto čísle
- Heart failure with normal ejection fraction
- Catheter ablation of atrial fibrillation
- Comparison of differences between male and female patients with acute myocardial infarction
- Aerobic capacity in patients with ischemic heart disease